Alto Neuroscience Raises Capital to Advance ALTO-207
I'm LongbridgeAI, I can summarize articles.Alto Neuroscience raised approximately $93.9 million via a registered direct offering of 3,776,436 shares at $26.48 per share. Proceeds will fund the accelerated clinical development of ALTO-207 for treatment-resistant depression, including an additional Phase 3 trial, and general working capital.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Alto Neuroscience, Inc. ( (ANRO) ) has issued an update.
On July 13, 2026, Alto Neuroscience entered into an underwriting agreement with a syndicate led by BofA Securities to sell 3,776,436 shares of common stock in a registered direct offering at $26.48 per share. The transaction is expected to generate approximately $93.9 million in net proceeds, with closing anticipated on July 14, 2026, subject to customary conditions.
Alto plans to use the funds, together with existing cash, to accelerate and expand clinical development of its ALTO-207 candidate, including a planned additional Phase 3 trial as a monotherapy for treatment-resistant depression, and for general working capital. The capital raise underscores the company’s strategic push to advance late-stage assets in a competitive neuroscience and mental health drug development landscape, with implications for its growth trajectory and stakeholders’ expectations around future clinical milestones.
The most recent analyst rating on (ANRO) stock is a Buy
with a $28.00 price target.
To see the full list of analyst forecasts on Alto Neuroscience, Inc. stock,
see the ANRO Stock Forecast page.
Spark’s Take on ANRO Stock
According to Spark, TipRanks’ AI Analyst, ANRO is a Neutral.
The score is held back primarily by weak operating fundamentals—no revenue, large losses, and substantial cash burn—despite a notably stronger, low-debt balance sheet. Technicals are supportive with the stock trading above key moving averages and positive momentum indicators, while valuation remains challenging due to negative earnings and no dividend support. Recent corporate updates around strong cash and expanded Phase 3 plans provide a modest positive offset.
To see Spark’s full report on ANRO stock,
click here.
More about Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates in the biopharmaceutical and neuroscience sector, focusing on the development of novel treatments for psychiatric disorders. Its pipeline includes drug candidates such as ALTO-207, which targets treatment-resistant depression, positioning the company in the specialized market for advanced mental health therapeutics.
Average Trading Volume: 464,762
Technical Sentiment Signal: Buy
Current Market Cap: $983.7M